Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma in the IMmotion151trial.
Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab (Tecentriq) and bevacizumab (Avastin) for patients with metastatic renal cell carcinoma (mRCC) in the IMmotion151trial.
Both of these agents have proven to be active as monotherapies, and as such, it seemed rational to combine them. Additionally, VEGF has immune-suppressive effects, including promoting myeloid-derived suppressor cells, regulatory T cells, etc. By suppressing VEGF, the microenvironment is more favorable for the immunotherapy to act.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More